Professor Deborah White
Director, Cancer Program and Deputy Theme
School of Medicine
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Deborah White PhD FFSc (RCPA)Professor Deb White is the Director: Precision Cancer Medicine at the South Australian Health and Medical Research Institute (SAHMRI) in Adelaide, and Group Leader of the Acute Lymphoblastic Leukaemia Genomics and Functional Genomics Research Group. Deb is a Professor in both the Faculty of Health and Medical Sciences and the Faculty of the Sciences at the University of Adelaide. Deb's research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL). She leads her group of scientists and bioinformaticians in the interpretation of genomic data and the curation of clinical relevant genomic alterations in leukaemia patients. She has presented more than 200 papers at scientific meetings and authored more than 150 scientific publications. Deb established, led and federated the ALL Stream of The Australian Genomics Health Alliance (AGHA) now known as Australian Genomics, and was a member of the AGHA Executive. She is the ALL Scientific Co-Chair for the Zero Children's Cancer (ZCC: PRISM2) Genomics Initiative. Deb is a member of both the Australian and New Zealand Children’s Oncology Group (ANZCHOG)and the Australasian Leukaemia Lymphoma Group (ALLG) and is a recently elected member of the Board of Directors of both organisations. She is also a member of the Lab Sciences Committee for ALLG and the Leukaemia/Lymphoma Group of ANZCHOG. Locally Deb is an invited member of the Cancer Care – Precision Medicine Committee, Commission on Excellence and Innovation in Health (CEIH) SA Health. Internationally, Deb is the only invited Australian representative to the The Variant Interpretation for Cancer Collaboration (VICC) Executive Group {An initiative of the Global Alliance for Genomics and Health (GA4GH)}. Deb is the current convener of the New Directions in Leukaemia Research Meeting (NDLR 2021-) and is a Section Editor for 3 international journals. She is currently a member of 4 International Grant and Fellowship Review boards and 6 National. She has received a number of awards: Australian Society for Medical Research (ASMR) Leading Light (2014), the University of Adelaide James McWha medal (2016), the prestigious NHMRC Research Excellence Award (2019) and the Beat Cancer Women in Leadership Award (2020). From 2016-2018 (max. term) she was an invited member of the South Australian Premier's Scientific Advisory Board. She is a highly sought supervisor and Post-Doctoral mentor, having supervised/supervising 28 PhD students (20 complete), and 19 Honours.
Leukaemia Research Group - Precision Medicine Theme, Cancer Program, SAHMRI
Lead: Professor Deborah White
Email: deborah.white@sahmri.com
A/ RESEARCH PROJECT
Brief description of research area.
T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a genomically complex, high-risk disease affecting both children and adults. Novel, targeted treatments are urgently required to prevent drug resistance and relapse. T-ALL is characterised by recurrent gene fusions and concomitant structural abnormalities. Ongoing advances in next generation sequencing (NGS) have enabled classification of a diverse range of genomic alterations resulting in new T-ALL subtypes. Critically, the wealth of genomic information available has identified new and recurrent genomic lesions but their biological and clinical implications remain unclear. Incorporating the knowledge gained through NGS into clinical care presents a major challenge.
Currently, up to 30% of paediatric/adolescent T-ALL patients relapse with subsequent poor overall survival; the outcome is worse for adult patients with long-term survival rates after relapse below 10%. The over-arching focus of my studies is the generation of patient-derived xenograft (PDX) and transgenic mouse models of T-ALL from patient samples received in the laboratory. These models will be used to (1) examine re-purposing drugs and testing novel therapies; and (2) provide therapeutic options for pre-emptive intervention in the case of therapy-resistant disease. Central nervous system (CNS) involvement is common in relapsed ALL but drivers of this aggressive disease are poorly defined. This project will use imaging studies to track specific disease subtypes demonstrating CNS penetration.
Research Project 1 - Dr Laura Eadie
Title: Evaluation of leukaemic invasion and penetrancein mouse models of ALL.
Project description:
Our laboratory is the National Referral Centre for genomic screening of ALL cases allowing identification of genomic alterations in a large number of patients.Establishment of PDX models from these patient samples is ongoing. Recent PDXs have resulted in leukaemic engraftment within the brain, indicative of CNS involvement and suggesting an aggressive disease. CNS penetration in ALL is a significant un-met clinical need, however, the pathogenesis of CNS disease, the underlying genomic determinants and the biology driving CNS penetration remain poorly understood and targeted therapies are limited.
Additional PDX models resulted in rapid detection of leukaemic cells within the blood, but not the bone marrow or brain, highlight the complexity of individual leukaemias and the need for real-time disease imaging and tracking. Fluorescently-tagged cells harvested from PDX models or transgenic cells harbouring genomic lesions of interest will be used to investigate CNS involvement. Cells isolated from leukaemic organs will be comprehensively characterised using molecular biology and NGS approaches. Surface receptor expression profiles of leukaemic cells will be examined to determine potential causes of invasion. Computational network biology analyses will be performed to define druggable pathways. Results from this project will inform on disease invasion and allow evaluation of treatment strategies for aggressive disease phenotypes in real-time.
Projects available for: Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Max Number of Students: 1
Category: Wet Lab
Research Area: Cancer Biology and Clinical Oncology
B/ RESEARCH PROJECT
Brief description of research area.
Acute Lymphoblastic Leukaemia (ALL) is the most common childhood cancer, and leading cause of non-traumatic death in children. For adolescents and young adults (AYA) with ALL the therapeutic outcomes are poor. Most older adults will die of their disease. The recent wealth of genomic information has seen the emergence of new lesions known to confer high-risk, and other recurrent fusions and gene deletions for which the biological and clinical implications remain unclear. Further, recent studies have implicated the human microbiome in ALL development, treatment response and life-long comorbidities. The major challenge is to incorporate knowledge gained through Next Generation Sequencing (NGS) into clinical care and to systematically identify druggabletargets and rational effective therapies to improve patient outcomes. To add to the complexity of therapeutic choice in ALL, immunotherapies (bi-specific T-cell engagers (BiTEs) and CAR-T cells), have shown efficacy in the relapsed/refractory setting, as a transplantation bridge. However, not all high-risk/relapsed ALL patients are eligible for immunotherapy, ~50% of patients experience severe hypersensitivity reactions and the long-term clinical sequelae remains unknown. Our laboratory is the National Referral Centre for genomic screening of ALL cases across all age groups, as such we sequence a large number of patients and have identified a significant number of alterations and novel gene fusions for investigation.
Research Project 2 –
Title: Cloning acute lymphoblastic leukaemia fusion genes and variants, functional characterisation and therapeutic responses.
Project description:
Recent advances in genomic profiling have defined B-cell Acute Lymphoblastic Leukeamia (B-ALL) as a heterogeneous disease with multiple subgroups characterised by distinct genetic alterations. Many genomic lesions in B-ALL are associated with alterations of cytokine receptors or their signaling pathway mediators, transcription factors or regulators of differentiation.Genomic lesions in ALL patients stratify with prognosis and using transcriptomic analysis, we have identified a number of poorly characterisedfusion genes and variants in patients. This project aims to clone full-length fusion-genes and gene variants from patient material into mammalian expression plasmids. This will allow in vitrocharacterisation in cell line models of aberrant signalling pathways that drive disease and assess therapeutic responses. This project will involve a range of molecular biology and cloning techniques including primer design, PCR Sanger sequencing, bacterial work, tissue culture and flow cytometry.
Projects available for: Third Year (Basic Science) / Honours
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Max Number of Students: 1
Category: Wet Lab
Research Area: Cancer Biology and Clinical Oncology
Research Project 3 – Dr Sue Heatley
Title: Investigation of resistance mechanisms to the bispecific T-cell engager (BiTE) blinatumomab in relapsed acute lymphoblastic leukaemia.
Project description:
Recently, a new compound of drug known as Bispecific T-cell engager (BiTE) has been approved for use in B-ALL by the Food and Drug Administration (FDA) and is currently undergoing clinical trials in Australia. Blinatumomab is a BiTE that enables an immunological response between the CD19 positive leukaemic cell and a cytotoxic CD3 positive T-cell. While the introduction of blinatumomab promises to be an exciting addition to the clinical arsenal, initial response rates in relapsed/refractory ALL have been ~43% and, as with other treatments, resistance is likely to occur. Immune evasion is a likely cause of resistance as well as loss of the CD19 target, leading to CD19 negative relapse and further investigation is warranted.
Relapsed patient samples that are identified as being treated with blinatumomab will be flow sorted by CD19 positivity. CD19 positive and CD19 negative populations will undergo mRNAseq to identify if a lineage switch has occurred and if the driving event is now present in the CD19 negative population. Differences in gene expression will also be interrogated.
Resistance will be modelled in-vitroby subjecting fusion constructs to incrementally increasing doses of blinatumomab, enabling further examination of potential immune evasion pathways.
Projects available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Max Number of Students: 1
Category: Wet Lab
Research Area: Cancer Biology and Clinical Oncology
| Date | Position | Institution name |
|---|---|---|
| 2024 - ongoing | Theme Leader: Precision Cancer Medicine | South Australian Health and Medical Research Institute |
| 2015 - ongoing | Affiliate Professor | University of Adelaide |
| 2015 - 2023 | Deputy Theme Leader (Precision Medicine) & Director of Cancer Research | South Australian Health and Medical Research Institute |
| 2013 - ongoing | Senior Principal Research Fellow | South Australian Health and Medical Research Institute |
| 2013 - ongoing | Affiliate Professor Medicine | University of Adelaide |
| 2013 - ongoing | Affiliate Professor Pediatrics | University of Adelaide |
| 2013 - 2015 | Director of Cancer Research | South Australian Health and Medical Research Institute |
| 2013 - ongoing | Adjunct Professor Faculty of Health Sciences | University of South Australia, Adelaide |
| 2013 - ongoing | Group Leader: ALL Genomics and Functional Genomics/Biology | South Australian Health and Medical Research Institute |
| 2011 - 2017 | Affiliate Associate Professor Medicine | University of Adelaide |
| 2011 - 2013 | Head of Research | SA Pathology |
| 2011 - 2013 | Adjunct Associate Professor | University of South Australia |
| 2011 - 2013 | Chief Medical Scientist and Scientific Head | University of Adelaide |
| 2000 - 2011 | Chief Medical Technician | SA Pathology |
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2021 | Award | Beat Cancer Women in Leadership Award | Cancer Council | Australia | - |
| 2019 | Fellowship | NHMRC Research Excellence Award | NHMRC | Australia | - |
| 2017 | Award | Light the Night Blue Ambassador. | Leukaemia Foundation of Australia | Australia | - |
| 2016 | Award | Shortlisted Candidate National Academy of Science Gottschalk Medal | - | - | - |
| 2016 | Award | Finalist Winnovation Award (Science and Medicine Category) | - | - | - |
| 2016 | Award | 2016 James McWha Medalist | - | - | - |
| 2014 | Award | Australian Society for Medical Research (ASMR) Leading Light for 2014 | - | - | - |
| 2013 | Award | 2013 Abstract accepted for the Presidential Symposium | - | - | - |
| 2012 | Award | 2012 Abstract accepted for the Presidential Symposium | - | - | - |
| 2011 | Recognition | Member of the Chief Investigative Team recognized by the NHMRC for one of the “Ten of the Best Project Grants” | - | Australia | - |
| 2011 | Award | Centre for Cancer Biology Prize for Highest Impact Paper 2009-2010 | - | Australia | - |
| 2009 | Distinction | Hanson Centre Clinical Researcher of the Year | - | Australia | - |
| 1994 | Award | Travel Award for Outstanding Young Scientific Investigators | Health Science Alliance | Australia | - |
| 1992 | Award | Travel Award for Outstanding Young Scientific Investigators | Health Science Alliance | Australia | - |
| 1988 | Recognition | Outstanding Achievement in the field of Haematology | University of South Australia | - | - |
| 1987 | Award | Travel Award for Outstanding Young Scientific Investigators | Health Science Alliance | Australia | - |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2011 | Faculty of Science Royal College of Pathologists | Australia | FFSc RCPA, Founding Fellow |
| 2008 | The University of Adelaide | Australia | PhD |
| Year | Citation |
|---|---|
| 2020 | Tavakoli, P. S., Eadie, L., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib (Vol. 4). Lippincott, Williams & Wilkins. DOI |
| Year | Citation |
|---|---|
| 2023 | White, D. L., Rehn, J. A., Schutz, C. E., Heatley, S. L., Eadie, L. N., Thomson, A., . . . Greenwood, M. (2023). Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies. In BLOOD Vol. 142 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI |
| 2023 | Eadie, L. N., Schutz, C. E., Page, E. C., Conlin, T. S., Heatley, S. L., Lagonik, E., . . . White, D. L. (2023). Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2023 | Thompson, J. F., Yeung, D. T., Grose, R. H., & White, D. L. (2023). Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5::JAK2 fusion I n Vitro: Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI |
| 2022 | Poudel, G., Yeung, D. T., White, D. L., Hughes, T., & Pagani, I. S. (2022). <i>PTPN11</i> Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph plus ALL Cells, but Are Sensitive to the Combination. In BLOOD Vol. 140 (pp. 3128-3129). LA, New Orleans: AMER SOC HEMATOLOGY. DOI |
| 2021 | Page, E. C., Heatley, S. L., Rehn, J., Yeung, D. T., Thomas, P. Q., & White, D. L. (2021). <i>HMGN1</i> expression Predisposes Down Syndrome Patients to Develop <i>P2RY8-CRLF2</i> acute Lymphoblastic Leukemia. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: ELSEVIER. DOI |
| 2018 | Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins. DOI |
| 2018 | Chan, L. N., Shojaee, S., Hurtz, C., Auer, F., Chen, Z., Cosgun, K. N., . . . Muschen, M. (2018). Divergent Evolutionary Trajectories of Erkand Stat5-Activating Lesions in Acute Lymphoblastic Leukemia. In BLOOD Vol. 132 (pp. 2 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI |
| 2018 | Yeung, D. T., Grigg, A. P., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2018). Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. In BLOOD Vol. 132 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS7 |
| 2017 | Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood Vol. 130 (pp. 1597). Atlanta: American Society of Hematology. |
| 2016 | Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group. |
| 2016 | Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . White, D. L. (2016). <i>In Vitro</i> Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance Implications for Targeted Therapy. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2016 | Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI |
| 2016 | Zaliova, M., Moorman, A. V., Cazzaniga, G., Stanulla, M., Harvey, R. C., Roberts, K. G., . . . Zuna, J. (2016). Characterization of leukemias with ETV6-ABL1 fusion. In Proceedings of the 57th Annual Meeting of the American-Society-of-Hematology, as published in Haematologica Vol. 101 (pp. 1082-1093). Orlando, FL: Ferrata Storti Foundation. DOI Scopus81 WoS73 Europe PMC65 |
| 2016 | Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. M. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2016 | Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). MODELLING PONATINIB RESISTANCE IN BCR-ABL1+CELL LINES: IMPLICATIONS FOR PONATINIB THERAPY. In HAEMATOLOGICA Vol. 101 (pp. 182-183). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2015 | Eadie, L. N., Hughes, T. P., & White, D. L. (2015). The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2015 | Kok, C. H., Leclercq, T. M., Watkins, D., Yeung, D. T., Saunders, V. A., White, D. L., & Hughes, T. P. (2015). A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Wang, J., Kok, C. H., Leclercq, T. M., Saunders, V. A., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2015). High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγle) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2014 | Eadie, L. N., Hughes, T. P., & White, D. L. (2014). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to over TKI resistance. In NDLR Abstract Handbook Vol. 122 (pp. 2 pages). Noosa, QLD: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2013 | White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. In Blood Vol. 122 (pp. 256). American Society of Hematology. DOI |
| 2013 | Eadie, L., Hughes, T. P., & White, D. L. (2013). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to overt TKI resistance. In Blood Vol. 122 (pp. 5157). New Orleans, Louisiana: American Society of Hematology. DOI |
| 2013 | Gordon, J. E. A., Bailey, C. G., Rasko, J., Ritchie, W., Watkins, D. B., White, D. L., . . . Hughes, T. P. (2013). MicroRNA Dysregulation in Newly Diagnosed Chronic Myeloid Leukaemia Patients. In BLOOD Vol. 122 (pp. 1 page). New Orleans, LA: AMER SOC HEMATOLOGY. DOI |
| 2011 | White, D. L., Saunders, V. A., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. P. (2011). The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients. In BLOOD Vol. 118 (pp. 735). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2011 | Watkins, D. B., Kok, C. H., Hughes, T. P., Slader, C., D'Andrea, R., & White, D. L. (2011). Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. In BLOOD Vol. 118 (pp. 727). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34<SUP>+</SUP> CML Progenitors to Dasatinib-Induced Cell Death. In BLOOD Vol. 118 (pp. 1599). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2011 | Wang, J., Hughes, T. P., Kok, C. H., Saunders, V. A., Frede, A., GrootObbink, K., . . . White, D. L. (2011). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. In BLOOD Vol. 118 (pp. 1493-1494). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | White, D. L., Lu, L., Clackson, T. P., Saunders, V. A., & Hughes, T. P. (2011). ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib. In BLOOD Vol. 118 (pp. 1180). San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2010 | Soverini, S., Angelini, S., Turrini, E., Burnett, M., Ravegnini, G., Thornquist, M., . . . Martinelli, G. (2010). Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib - A TOPS Correlative Substudy. In BLOOD Vol. 116 (pp. 293-294). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Tang, C., Schafranek, L., Watkins, D., Parker, W. T., Prime, J., White, D. L., & Hughes, T. (2010). Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression. In BLOOD Vol. 116 (pp. 1385). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2010 | White, D. L., Saunders, V., Andrew, M., Rofe, A., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Imatinib PK: Observations From the TIDEL II Study.. In BLOOD Vol. 116 (pp. 943). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | White, D. L., Saunders, V., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study. In BLOOD Vol. 116 (pp. 160-161). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS10 |
| 2010 | Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida. |
| 2010 | Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology. DOI |
| 2010 | Hiwase, D. K., Engler, J., Saunders, V., White, D. L., & Hughes, T. (2010). In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34<SUP>+</SUP> Progenitors Is Not Significantly Different Than That Observed In CD34<SUP>-</SUP> Mature Cells.. In BLOOD Vol. 116 (pp. 517). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2009 | Osborn, M. P., Branford, S., White, D. L., Seymour, J. F., Columbus, R., Taylor, K., . . . Hughes, T. P. (2009). Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.. In BLOOD Vol. 114 (pp. 461-462). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | White, D. L., Saunders, V. A., Frede, A., Dang, P., Zrim, S., Osborn, M. P., . . . Hughes, T. (2009). The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial. In BLOOD Vol. 114 (pp. 209-210). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Osborn, M. P., White, D. L., Saunders, V. A., Cambareri, B., Branford, S., Menelaou, A., . . . Hughes, T. P. (2009). Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.. In BLOOD Vol. 114 (pp. 465). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Soverini, S., Angelini, S., Turrini, E., Pane, F., Quarantelli, F., Hughes, T. P., . . . Martinelli, G. (2009). Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity. In BLOOD Vol. 114 (pp. 1271). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Engler, J. R., Frede, A., Saunders, V. A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2009). OCT-1 Activity in CML CD34+Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity. In BLOOD Vol. 114 (pp. 861). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2008 | Hiwase, D. K., White, D. L., Saunders, V. A., Melo, J. V., Kumar, S., & Hughes, T. P. (2008). Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. In BLOOD Vol. 112 (pp. 397). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2008 | Engler, J. R., Frede, A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2008). Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. In BLOOD Vol. 112 (pp. 80). San Francisco, CA: AMER SOC HEMATOLOGY. WoS2 |
| 2008 | Esposito, N., Quarantelli, F., Luciano, L., Izzo, B., Peluso, A. L., Picardi, M., . . . Pane, F. (2008). The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. In BLOOD Vol. 112 (pp. 404). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2008 | Mullighan, C. G., Radtke, I., Zhang, J., Phillips, L. A., Su, X., Ma, J., . . . Downing, J. R. (2008). Genome-Wide Analysis of Genetic Alterations in Chronic Myelogenous Leukemia. In BLOOD Vol. 112 (pp. 397-398). San Francisco, CA: AMER SOC HEMATOLOGY. WoS9 |
| 2008 | White, D. L., Saunders, V. A., Kalebic, T., & Hughes, T. P. (2008). The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients. In BLOOD Vol. 112 (pp. 405). San Francisco, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2008 | White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In BLOOD Vol. 112 (pp. 1093-1094). San Francisco, CA: AMER SOC HEMATOLOGY. WoS3 |
| 2008 | White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In Blood Vol. 112 (pp. 3187). American Society of Hematology. DOI |
| 2007 | Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology. DOI |
| 2007 | Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS7 |
| 2005 | White, D. L., Saunders, V. A., Engler, J., Dang, P., Zannettino, A. C., Cambareri, A., . . . Hughes, T. P. (2005). Low baseline intrinsic sensitivity to imatinib (high IC50) in CML patients is due to reduced Oct-1 mediated influx. Intrinsic sensitivity to AMN107 does not correlate with that of imatinib and uptake of AMN107 is not Oct-1 mediated.. In BLOOD Vol. 106 (pp. 315A). Atlanta, GA: AMER SOC HEMATOLOGY. |
| 2005 | White, D. L., Saunders, V. A., Branford, S., Lynch, K., To, L. B., & Hughes, T. P. (2005). The in-vivo level of imatinib induced kinase inhibition achieved in de-novo CML patients during the first 28 days of therapy is a powerful predictor of molecular outcome.. In BLOOD Vol. 106 (pp. 132A). Atlanta, GA: AMER SOC HEMATOLOGY. |
| 2004 | White, D. L., Saunders, V. A., Branford, S., Lyons, B., & Hughes, T. P. (2004). The combination of intrinsic sensitivity to imatinib and Sokal prognostic score is strongly predictive of molecular response in newly diagnosed CML patients treated with imatinib.. In BLOOD Vol. 104 (pp. 288A-289A). San Diego, CA: AMER SOC HEMATOLOGY. |
| Year | Citation |
|---|---|
| 2022 | Thomson, A., Rehn, J., Heatley, S., Eadie, L., McClure, B., Page, E., . . . White, D. (2022). Benchmarking the detection rate of IGH gene fusions in B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) Conference. |
| 2021 | Heatley, S. L., Page, E. C., Eadie, L. N., McClure, B. J., Rehn, J., Yeung, D. T., . . . White, D. L. (2021). Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2021 | Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy. |
| 2021 | McClure, B., Heatley, S., Grose, R., & White, D. (2021). Activation of the immune cell repertoire in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS). |
| 2021 | Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS). |
| 2021 | Heatley, S., Rehn, J., Breen, J., Moore, A., Sutton, R., Osborn, M., & White, D. (2021). Using single cell mRNAseq to interrogate the genomic consequences of Ph-like acute lymphoblastic leukaemia in adolescents. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS). |
| 2020 | Poudel, G., Yeung, D., White, D., Hughes, T., & Pagani, I. (2020). Understanding the mechanisms of imatinib resistance in a Ph+ acute lymphoblastic leukaemia cell line. Poster session presented at the meeting of The 59th ASMR National Scientific Conference. |
| 2020 | Page, E., Heatley, S., Thomas, P., & White, D. (2020). HMGN1 is necessary for Down Syndrome leukaemic cell proliferation and cooperates with CRLF2 for leukaemic transformation. Poster session presented at the meeting of The 59th ASMR National Scientific Conference. |
| 2020 | Eadie, L., Heatley, S., McClure, B., Schutz, C., Breen, J., Hughes, T., . . . White, D. (2020). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group. |
| 2020 | McClure, B., Heatley, S., Grose, R., Yeung, D., & White, D. (2020). Activation of the immune cell repertoire in B-cell acute lymphoblastic leukaemia.. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group. |
| 2020 | Page, E., Heatley, S., Thomas, P., & White, D. (2020). Inducible Knockout of HMGN1 in an In Vivo xenograft Model Reduces Down Syndrome Leukemic Burden and Increases Survival Outcomes. Poster session presented at the meeting of 62nd ASH ANNUAL MEETING AND EXPOSITION. |
| 2020 | Downes, C. E. J., McClure, B. J., Rehn, J., Breen, J., Bruning, J. B., Yeung, D. T., & White, D. L. (2020). Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an <i>in Vitro</i> model of a High-Risk Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: ELSEVIER. DOI WoS2 |
| 2020 | Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: ELSEVIER. DOI WoS1 |
| 2020 | Tavakoli, P., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent Activation of JAK/STAT Signaling Plays an Important Role in<i>in Vitro</i>Jaki Resistance in <i>TYK2</i>-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: ELSEVIER. DOI |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting). |
| 2020 | Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Targeted pseudo-alignment technique for rapid and accurate identification of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of 14th Annual Florey Postgraduate Conference. Adelaide, South Australia. |
| 2020 | Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT. |
| 2020 | Forgione, M. O., McClure, B. J., Eadie, L. N., & White, D. L. (2020). CD44 and its ligand osteopontin are upregulated specifically in KMT2A-AFF1 T-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent activation of JAK/STAT signaling plays an important role in in vitro Jaki resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of 62nd Annual Meeting of the American Society of Hematology. San Diego, California (virtual conference). |
| 2019 | Page, E. C., Heatley, S. L., Yeung, D. T., Thomas, P. Q., & White, D. L. (2019). A Novel Role for <i>HMGN1</i> in Down Syndrome Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER. DOI |
| 2019 | Yeung, D. T., Shanmuganathan, N., Grigg, A., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2019). Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER. DOI WoS2 |
| 2019 | Yeung, D. T., Grigg, A., Shanmuganathan, N., Solterbeck, A. C., White, D. L., Branford, S., . . . Hughes, T. P. (2019). Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER. DOI |
| 2019 | El Khawanky, N., Hughes, A., Yu, W., Taromi, S., Clarson, J., Lopez, A. F., . . . Zeiser, R. (2019). Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2019 | Cario, G., Leoni, V., Conter, V., Attarbaschi, A., Zaliova, M., Sramkova, L., . . . Biondi, A. (2019). Poor Prognosis in Children with ABL-Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI |
| 2019 | Tavakoli, P. S., Eadie, L., Heatley, S. L., & White, D. L. (2019). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting 2019. Christchurch, New Zealand. |
| 2019 | Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany. |
| 2019 | Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2019 | Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L., Schutz, C. E., . . . White, D. L. (2019). Investigating “alignment-free” computational techniques for the accurate identification of Acute Lymphoblastic Leukaemia (ALL) gene fusion events. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. |
| 2019 | Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. |
| 2019 | Yeung, D., Greenwood, M., Rehn, J., Heatley, S., McClure, B., Eadie, L., . . . White, D. (2019). High risk genomic alterations identified at the time of diagnosis are strongly associated with MRD and subsequent poor outcomes in AYA ALL patients treated on a pediatric inspired chemotherapy regimen. Poster session presented at the meeting of Blood. Orlando, CA: American Society of Hematology. DOI |
| 2018 | Downes, C., McClure, B., & White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at the meeting of Childhood Leukaemia and Lymphoma Symposium. Helsinki, Finland. |
| 2018 | Asari, K., Leclercq, T., Srihari, S., Fitter, S., Yeung, D., Hughes, T., . . . White, D. L. (2018). in vitro modelling of Ph-like ALL uncovers novel genomic alterations associated with TKI-resistance as a consequence of targeted therapy. Poster session presented at the meeting of Childhood Leukaemia and Lymphoma Symposium. Helsinki, Finland. |
| 2018 | Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . . . White, D. L. (2018). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of 23rd Congress of European Hematology Association. Stockholm, Sweden. |
| 2018 | Downes, C. E., McClure, B. J., Heatley, S. L., Yeung, D. T., & White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at the meeting of NDLR. |
| 2018 | Heatley, S. L., McClure, B. J., Kok, C., Sadras, T., Dang, P., Galbraith, K., . . . White, D. L. (2018). Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing. Poster session presented at the meeting of NDLR. |
| 2018 | Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients. Poster session presented at the meeting of NDLR. |
| 2018 | Eadie, L. N., Mullighan, C., & White, D. L. (2018). Mutations to the transcription factor MYB alter cellular localization and decrease degradation likely enhancing oncogenicity in patients with T-cell ALL. Poster session presented at the meeting of NDLR. |
| 2018 | Lu, L., Kok, C., Saunders, V., Nievergall, E., White, D. L., & Hughes, T. P. (2018). TGF-α predicts TKI treated CML patients who fail to achieve early molecular response. Poster session presented at the meeting of NDLR. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of APG Student Awards. |
| 2018 | Page, E. C., Heatley, S. L., Thomas, P., & White, D. L. (2018). Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of ASMR. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk JAK2 fusion in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR. |
| 2018 | Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of ASMR. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and Characterisation of Ruxolitinib Resistant Mutations in JAK2-rearranged B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of AGTA. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of mutations that cause ruxolitinib resistance in Pro-B cells driven by a high-risk B-ALL JAK2-fusion.. Poster session presented at the meeting of ANZCHOG. |
| 2018 | Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of SAHMRI Scientific Seminar. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of SAHMRI Scientific Seminar. |
| 2018 | Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of 12th Annual Florey postgraduate Conference. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium. |
| 2018 | Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium. |
| 2018 | Osborn, M., Dalla-Pozza, L., Trahair, T., Sutton, R., White, D. L., Fleming, S., & Greenwood, M. (2018). The Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 Trial: A Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukaemia (ALL).. Poster session presented at the meeting of Global AYA Cancer Congress. |
| 2017 | El-Khawanky, N., Hughes, A., Yu, W., Clarson, J., Lopez, A. F., Brown, M., . . . Yong, A. (2017). CD123 Chimeric Antigen Receptor T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of HAA. |
| 2017 | El-Khawanky, N., Hughes, T. P., Clarson, J., Yu, W., White, D. L., & Yong, A. (2017). Anti-CD123 Chimeric Antigen Receptor (CAR) T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of ASMR. |
| 2017 | McClure, B. J., Heatley, S. L., Kok, C., Sadras, T., An, J., Quek, K., . . . White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult pre-B-ALL patients. Poster session presented at the meeting of ANZCHOG. |
| 2017 | Heatley, S. L., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk-Adapted Treatment. Poster session presented at the meeting of ANZCHOG. |
| 2017 | Asari, K., Sadras, T., Srihari, S., Fitter, S., An, J., Zannettino, A. C., . . . White, D. L. (2017). in vitro Modelling of Ph-like ALL Fusions Uncovers Novel Kinase-domain Mutations as a Mode of TKI-resistance and Potential Consequence of Targeted TKI Therapy. Poster session presented at the meeting of ANZCHOG. |
| 2017 | McClure, B. J., Heatley, S. L., Sadras, T., Sutton, R., & White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult Australian pre-B-acute lymphoblastic leukaemia. Poster session presented at the meeting of IBFM. |
| 2017 | Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . Hughes, T. P. (2017). Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Poster session presented at the meeting of 59th ASH Annual Meeting & Exposition. |
| 2017 | Hughes, A., Clarson, J., White, D. L., Yeung, D., Hughes, T. P., & Yong, A. S. M. (2017). Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. WoS4 |
| 2017 | Yeung, D., Grigg, A., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2017). Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. |
| 2017 | Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J., Saunders, V. A., Prime, J. A., . . . Ross, D. M. (2017). COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION. |
| 2017 | Downes, C. E., McClure, B. M., Heatley, S. H., Sadras, T. S., Hughes, T. H., Kok, C. K., . . . White, D. W. (2017). Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster session presented at the ASMR SA Scientific Meeting. Adelaide. |
| 2017 | Heatley, S., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Poster session presented at the meeting of Abstracts of the 57th Annual Meeting of the American Society of Hematology, as published in Blood. Orlando, FL: American Society of Hematology. DOI WoS2 |
| 2016 | Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I., . . . White, D. (2016). HIGH GENE EXPRESSION OF HIST1H2AG AND HIST1H4A REDUCES IMATINIB UPTAKE INTO CML CELLS AND PREDICTS POOR RESPONSE TO FRONTLINE IMATINIB THERAPY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2016 | Heatley, S., Sadras, T., kok, C., Venn, N., Revesz, T., Osborn, M., . . . White, D. L. (2016). Australian Children with Ph-like ALL enrolled to ANZCHOG ALL8 had a high prevalence of relapse despite risk adapted treatment. Poster session presented at the meeting of CLS SCIENTIFIC PROGRAMME, Refractory Leukemia and Miscellaneous. Athens. |
| 2016 | Lock, R., Dollai, S., Sia, K., Daly, R., Rafferty, M., White, D. L., . . . Revesz, T. (2016). Quantitative Phosphotyrosine Profiling of patient derived xenografts identifies therapeutic targets in paediatric ALL. Poster session presented at the meeting of .. Athens. |
| 2016 | Sadras, T., Heatley, S., Dang, P., Kok, C., Quek, K., Nievergall, E., . . . White, D. L. (2016). A nine-gene signature defines 2 groups of CRLF2 rearranged B-ALL patients with distinctive genetic features. Poster session presented at the meeting of .. Athens. |
| 2016 | Pagani, I. S., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . Ross, D. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia. Poster session presented at the meeting of .. Barcelona, Spain. |
| 2016 | Eadie, L., Saunders, V., Branford, S., Hughes, T., & White, D. (2016). Resistance mechanisms of the new allosteric inhibitor ABL001. Poster session presented at the meeting of ,. Houtson, USA. |
| 2016 | Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). ABCC6 plays a significant role in the transport of nilotinib in both cells lines and primary patient cells, and may contribute to resistance. Poster session presented at the meeting of ,. Houston, USA. |
| 2016 | Saunders, V. A., Wang, J., Lu, L., Eadie, L. N., McLean, J. A., Goyne, J. M., . . . Hughes, T. P. (2016). A Low Concentration of ABL001 Potentiates <i>In Vitro</i> TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2016 | Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance. Poster session presented at the meeting of .. San Diego, USA: AMER SOC HEMATOLOGY. DOI |
| 2016 | Eadie, L., Hughes, T., & White, D. (2016). ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment. Poster session presented at the meeting of Abstract presented at the New Directions in Leukaemia Research 2016 Meeting. Noosa, QLD. |
| 2016 | Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Abl001 Is Susceptible To Resistance Mediated By Overexpression Of Drug Transporters Abcb1 and Abcg2. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Sadras, T., Heatley, S., Kok, C., Quek, K., Dang, P., Nievergall, E., . . . White, D. L. (2016). CRLF2 rearranged B-ALL cases with a Ph-like gene signature are enriched for JAK2 mutations. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). Modelling ponatinib resistance in BCR-ABL1+ cell lines: implications for ponatinib therapy. Poster session presented at the meeting of New Directions in Leukaemia Research 2016. Noosa, QLD. |
| 2016 | McClure, B., Heatley, S., Sadras, T., Nievergall, E., Kok, C., Dang, P., . . . White, D. L. (2016). Identification of a significantly high prevalence of relapse in Australian children with Ph-like ALL. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Asari, K., Heatley, S., Leclercq, T., Fitter, S., Zannettino, A., Hughes, T., & White, D. L. (2016). In vitro Modelling of Therapeutic Resistance to Elucidate Mechanisms of TKI-Resistant High-Risk ALL. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Pagani, I., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . White, D. L. (2016). Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukemic clone?. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Eadie, L., Dang, P., Saunders, V., Hughes, T., & White, D. L. (2016). The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients treated sequentially with imatinib and nilotinib: A TIDEL II sub-study. Poster session presented at the meeting of ,. Adelaide, SA. |
| 2016 | White, D. L., McClure, B., Heatley, S., Sadras, T., Quek, K., & Hughes, T. (2016). Investigation of the transforming capacity of a recently identified EP300-ZNF384 fusion gene in adult acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Leow, B., Eadie, L. N., Leclercq, T., & White, D. L. (2016). Drug resistance in CML: heterogeneity, selection, and clonal architecture. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . . . White, D. L. (2016). Investigating Modes of Therapeutic Resistance via In Vitro Modelling of TKI-resistant High-Risk Philadelphia-chromosome-positive and Philadelphia-chromosome-like Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Galbraith, K., Sadras, T., McClure, B., Heatley, S., & White, D. L. (2016). Identification of novel therapeutic targets in CRLF2 rearranged acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Understanding the mechanism of secondary resistance to Azacitidine in Myelodysplastic syndromes using the cell-line model MOLM-13. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I. S., . . . White, D. L. (2016). High Gene Expression of hist1h2ag and hist1h4a Reduces Imatinib Uptake into CML Cells and Predicts Poor Response to Frontline Imatinib Therapy. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Heatley, S., Sadras, T., McClure, B., Kok, C. H., Dang, P., Nievergall, E., . . . White, D. L. (2016). The Incidence of Ph-like Acute Lymphoblastic Leukaemia (ALL) Increases with Age and is Characterised by Poor Outcome. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Van der Hoek, M., Heatley, S., . . . Ross, D. (2016). Mitochondrial DNA Mutations at Diagnosis are Linked to Response in TKI treated Chronic Myeloid Leukaemia Patients. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Watts, S., Wee, A., Saunders, V., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Determining Mechanisms of Resistance to Azacitidine (Aza) in Myelodysplastic (MDS) Syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T., & White, D. L. (2016). Modelling Ponatinib Resistance In BCR-ABL1+ Cell Lines: Implications For Ponatinib Therapy. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Hughes, A., Clarson, J., White, D. L., Ross, D. M., Hughes, T. P., & Yong, A. S. (2016). Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS7 |
| 2015 | Zaliova, M., Moorman, A., Cazzaniga, G., Stanulla, M., Harvey, R., Roberts, K., . . . Zuna, J. (2015). Characterization of Leukemias with ETV6-ABL1 Fusion. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. |
| 2014 | Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T. P., & White, D. L. (2014). Modeling Ponatinib Resistance in <i>BCR-ABL1</i>+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naive Patients. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY. |
| 2014 | Yeung, D. T., Vidovic, L., Tang, C., White, D. L., Branford, S., Hughes, T. P., & Yong, A. S. M. (2014). KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2014 | Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology. DOI WoS1 |
| 2014 | Parker, W. T., Phillis, S. R., Yeung, D. T., Lawrence, D., Schreiber, A., Wang, P., . . . Branford, S. (2014). Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2013 | White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. |
| 2013 | White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of <i>In Vivo</i> Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY. WoS1 |
| 2013 | Wang, J., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2013). Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY. DOI |
| 2013 | White, D. L., Eadie, L., & Hughes, T. (2013). Increasing Expression of the Efflux Transporter ABCB1 may Predispose CML Cells to Overt TKI Resistance.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. |
| 2012 | White, D. L., Saunders, V., Yeung, D., Grigg, A., & Hughes, T. (2012). Early Molecular Response to Imatinib in CP-CML Patients: The Significance of Early Dose Intensity and OCT-1 Activity in Responders and Efficacy of Dose Escalation and Switch to Nilotinib in Non-Responders.. Poster session presented at the meeting of American Society of Haematology. Atlanta, USA. |
| 2012 | Watkins, D. B., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2012). Global DNA methylation analysis identifies key pathway differences between poor (low OCT-1 activity) and standard risk CP-CML patients at diagnosis. Poster session presented at the meeting of “Abstracts of the 54th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood. Atlanta, GA: America Society of Hematology. |
| 2012 | Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS8 |
| 2012 | Nievergall, E., White, D. L., Yong, A. S. M., Ramshaw, H. S., Busfield, S. J., Vairo, G., . . . Hiwase, D. K. (2012). Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY. DOI |
| 2012 | Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS3 |
| Year | Citation |
|---|---|
| 2017 | Downes, C. E. (2017). Cloning, Signalling Characterisation and JAK2 Inhibitor-Resistance of Two JAK2 Fusions in High-Risk B-ALL. (Undergraduate Dissertation). |
| Year | Citation |
|---|---|
| 2025 | Eadie, L. N., McDougal, D. P., Lagonik, E., Schutz, C. E., Conlin, T. S., Page, E. C., . . . White, D. L. (2025). The 5’ fusion partner modulates response to the STAMP inhibitor asciminib in <i>ABL</i> -rearranged ALL. DOI |
Peer Reviewed Research Funding
I have been successful in securing competitive research funding (Approx $30million).
International Competitive Schemes LLS (CML. 2009 and 2016) and the Hughes Foundation/USC Parker Institute (ALL 2015, 2016) NHMRC (2007 (CML),2009(CML), 2012(CML), 2012 (ALL), 2013(CML),and 2014(CML), Leukaemia Foundation of Australia (LFA) (2008 2012 (CML) and 2013 (ALL)), Cancer Council of SA (2011 (CML) and 2012 (ALL) and Channel 7 2015 (ALL). NHMRC TCR in genomics now (AGHA)(ALL $25 million). A significant outcome of the work of my group has been the successful translation into clinical practice. In excess of $5.5 million in Pharmaceutical funding over the last 10 years has been secured.
International Peer Reviewed Competitive Schemes
|
National Peer Reviewed Competitive Schemes (Other than NHMRC)
|
NHMRC Schemes (peer reviewed) (>$13 million)
|
Industry Funding - Granted (>$5.5 million)
|
Local Schemes - Granted
| 2024 | Contributing Haematologists Committee Research Grants |
Improving outcomes in DUX4 rearranged B-ALL through improved genomic subtyping, rapid diagnosis and molecular monitoring |
David Yeung, Jacqueline Rehn, Deborah White |
| 2023 | Contributing Haematologists Committee Research Grants |
Acute Lymphoblastic Leukaemia: Understanding the factors that determine response to new immune-based therapies |
David Yeung, Deborah White, David Lynn |
| 2017 | Contributing Haematologists Committee Research Grants | Evaluate role of cellular influx and efflux pumps in Azacitidine resistance |
Devendra Hiwase, Timothy Hughes, Deborah White and Amilia Wee |
| 2017 |
Contributing Haematologists Committee Research Grants |
Functional effects of mitochondrial mutations in CML |
David Ross and Deborah White |
| 2016 | Contributing Haematologists Committee Research Grants | Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukaemic clone | David Ross and Deborah White |
| 2016 | Contributing Haematologists Committee Research Grants | Identification of mechanisms of drug resistance in models of Ph-like ALL treated with targeted therapies | David Yeung Deborah White |
Undergraduate Lectures
Guest Lecturer CML Biology 3rd Year Health and Biotech, University of SA
Guest Lecturer 3rd Year Pharmacology
Guest Lecturer 3rd Year Biomedical Science
Guest lecture series Final Year Advanced Biomedical Science + associated tutorials
Project Mentor to third year MBBS students; Research Project Design: ALL
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2024 | Principal Supervisor | Clinical Transcriptomic Sequencing Analysis Workflows for Acute Lymphoblastic Leukaemia (ALL): Improving Subtype Characterisation in Complex Fusion Events | Doctor of Philosophy | Doctorate | Full Time | Mrs Ashlee Jean Thomson-Roberts |
| 2024 | Principal Supervisor | Identifying Predictors of CNS involvement in Acute Lymphoblastic Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Mr Luke Jacob Quinlan |
| 2024 | Co-Supervisor | Investigating the role of lipid metabolism in chronic myeloid leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Molly Gladys Tolland |
| 2023 | Co-Supervisor | Modelling co-occurring mutations in T-cell Acute Lymphoblastic Leukaemia to enhance treatment options and maximise the power of next generation sequencing | Doctor of Philosophy | Doctorate | Full Time | Mr Maxim Jon Buckley |
| 2023 | Co-Supervisor | Discovery of novel metabolic targets against lDH1-mutant intrahepatic cholangiocarcinoma | Doctor of Philosophy | Doctorate | Full Time | Mrs Tasnova Tasnim Nova |
| 2023 | Principal Supervisor | Interrogating the DUX4 rearranged subtype of B cell Acute Lymphoblastic Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Mr Thomas Oliver McGovern |
| 2023 | Principal Supervisor | Exploring the impact of the gut microbiota on the clinical scenario in Acute Lymphoblastic Leukaemia patients | Doctor of Philosophy | Doctorate | Full Time | Miss Cate Viktorija Cheney |
| 2022 | Co-Supervisor | A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery | Doctor of Philosophy | Doctorate | Full Time | Miss Maha Kamel |
| 2021 | Principal Supervisor | Investigation of current, innovative treatments and the roles of secondary genomic lesions in BCR-ABL1 positive leukaemias | Doctor of Philosophy | Doctorate | Part Time | Mr Elias Lagonik |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2022 - 2025 | Principal Supervisor | Genomics, Diagnosis, Novel Targeted Therapies and Characterisation of the Drivers of Relapse in Philadelphia Chromosome-Like Acute Lymphoblastic Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Jane Frances Thompson |
| 2019 - 2023 | Co-Supervisor | Bioinformatic approaches to variant detection and subtype classification in acute lymphoblastic leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Jacqueline Ann Rehn |
| 2019 - 2022 | Principal Supervisor | Characterising KMT2A and MLLT10 Rearranged Acute Lymphoblastic Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Michelle Olivia Forgione |
| 2018 - 2022 | Principal Supervisor | Precision Medicine Approaches for JAK2-Rearranged Acute Lymphoblastic Leukaemia: The Efficacy of Targeted Therapies and Molecular Mechanisms of Drug Resistance | Doctor of Philosophy | Doctorate | Full Time | Miss Charlotte Emma-Jeane Toomes |
| 2018 - 2021 | Principal Supervisor | Exploring the cooperation and targetability of CRLF2 and HMGN1 in Down Syndrome Acute Lymphoblastic Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Elyse Chenae Page |
| 2017 - 2021 | Principal Supervisor | Characterising the novel MYB-TYK2 fusion gene in high-risk acute lymphoblastic leukaemia: oncogenic potential, effective therapeutic strategies and In vitro modelling of drug resistance mechanisms | Doctor of Philosophy | Doctorate | Full Time | Miss Paniz Tavakoli Shirazi |
| 2016 - 2021 | Principal Supervisor | The Combined Treatment Efficacy of Anti-CD123 CAR T cells with Azacitidine for the Treatment of Acute Myeloid Leukaemia. | Doctor of Philosophy under a Jointly-awarded Degree Agreement with | Doctorate | Full Time | Miss Nadia El-Khawanky |
| 2015 - 2019 | Principal Supervisor | Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors In Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Mr Benjamin Chia Sing Leow |
| 2014 - 2018 | Principal Supervisor | In vitro Modelling of High-risk ALL Fusions Uncovers Genomic Alterations and Non-canonical Signalling Pathways as a Mode of TKI-Resistance - Implications for Targeted Therapy | Doctor of Philosophy | Doctorate | Full Time | Miss Kartini Asari |
| 2012 - 2014 | Co-Supervisor | The role of cytokines in governing the expansion of the T315I mutation in Chronic myeloid leukaemia | Master of Philosophy (Medical Science) | Master | Full Time | Dr Oi-Lin Lee |
| 2012 - 2016 | Principal Supervisor | In Vitro Investigation of Intracellular Ponatinib Transport and Modeling Ponatinib Resistence in BCR-ABL1+ Cell Lines: Implications for Therapeutic Strategies | Doctor of Philosophy | Doctorate | Full Time | Ms Liu Lu |
| 2012 - 2018 | Co-Supervisor | Personalized Medicine Support System for Chronic Myeloid Leukaemia Patients | Doctor of Philosophy | Doctorate | Full Time | Mrs Haneen Reda M Banjar |
| 2010 - 2014 | Co-Supervisor | Assessment of Critical Survival Mechanisms Exploited by BCR-ABL1+ Cells to Evade Tyrosine Kinase Inhibitor-Induced Death; Determination of Novel Therapeutic Targets in Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Lisa Schafranek |
| 2010 - 2014 | Principal Supervisor | Defining CP-CML patient subsets associated with poor imatinib uptake and response | Doctor of Philosophy | Doctorate | Full Time | Mr Dale Benjamin Watkins |
| 2009 - 2013 | Co-Supervisor | Nilotinib Efflux and Resistance Development: The Effects of Combination and Concomitant Therapies on the Transport and Efficacy of Nilotinib | Doctor of Philosophy | Doctorate | Full Time | Ms Laura Eadie |
| 2008 - 2013 | Co-Supervisor | Investigating Drugs that Enhance Imatinib Uptake and Factors which Contribute to the Functional Activity of OCT-1 in CML Cells | Doctor of Philosophy | Doctorate | Full Time | Miss Jueqiong Wang |
| 2008 - 2010 | Co-Supervisor | Evaluation of Anti-proliferative and Pro-apoptotic Effects of Tyrosine Kinase Inhibitors on CML-CD34+ Cells | Doctor of Philosophy | Doctorate | Full Time | APrf Devendra Hiwase |
| 2008 - 2011 | Co-Supervisor | Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Ms Jane Engler |
| 2008 - 2012 | Co-Supervisor | TKI Resistance in CML Cell Lines: Investigating Resistance Pathways | Doctor of Philosophy | Doctorate | Full Time | Mrs Carine Tang |
| Date | Role | Board name | Institution name | Country |
|---|---|---|---|---|
| 2023 - ongoing | Member | South Australian Genomics Consortium (SAGC) Advisory Board | SAGC | Australia |
| 2023 - ongoing | Director | Board of Directors Australian and New Zealand Children's Oncology Group (ANZCHOG) | ANZCHOG | Australia |
| 2023 - ongoing | Director | Board of Directors Australasian Leukaemia Lymphomas Group (ALLG) | ALLG | Australia |
| 2023 - ongoing | Board Member | SAGC Board of Directors | South Australian Genomics Centre | Australia |
| 2016 - ongoing | Member | Nuclear Fuel Cycle Royal Commission Consultation and Response Advisory (CARA) Board | - | - |
| Date | Role | Committee | Institution | Country |
|---|---|---|---|---|
| 2024 - ongoing | Member | VPCC executive Committee | Victorian Paediatric Cancer Consortium | Australia |
| 2023 - 2025 | Member | Braggs Comprehensive Cancer Centre (BCCC) Executive Committee | Braggs Comprehensive Cancer Centre | Australia |
| 2023 - ongoing | Member | DATA Access Committee for ZERO (ZERO-DAC) | ZERO | Australia |
| 2023 - ongoing | Member | BCCC Haematology Leadership Committee | Braggs Comprehensive Cancer Centre | Australia |
| 2022 - ongoing | Member | The Variant Interpretation for Cancer Collaboration (VICC) Executive Group | Global Alliance for Genomics and Health (GA4GH) | United States |
| 2022 - ongoing | Member | Australian and New Zealand Count-Me-In (CMI-ANZ) Scientific Advisory and Innovation Committee | VPCCC | Australia |
| 2022 - ongoing | Member | SAHMRI Gender Equity Committee | SAHMRI | Australia |
| 2021 - ongoing | Chair | SAHMRI Research Strategy and Leadership Committee | SAHMRI | Australia |
| 2021 - 2024 | Convener | New Directions in Leukemia Research Conference | NDLR | Australia |
| 2020 - 2020 | Member | New Directions in Leukemia Research Conference | NDLR | Australia |
| 2019 - ongoing | Member | Australian Leukemia and Lymphoma Group Lab Science Committee | Australian Leukemia and Lymphoma Group | Australia |
| 2018 - 2018 | Member | New Directions in Leukemia Research Conference | NDLR | Australia |
| 2017 - ongoing | Advisory Board Member | ANZCHOG Leukaemia Lymphoma Group | Australian and New Zealand Children's Hematology/ Oncology Group | Australia |
| 2016 - 2023 | Founder | Statewide Cancer Translational Research Group | SAHMRI | Australia |
| 2016 - 2016 | Member | Scientific Symposium Committee | South Australian Health and Medical Research Institutesa | Australia |
| 2016 - ongoing | Founder | SA Translational Cancer Research Group Meetings | - | Australia |
| 2016 - 2016 | Chair | Post Graduate Student Forum | Basil Hetzel Institute Research Day | Australia |
| 2016 - 2016 | Chair | SAHMRI Imaging Workshop | South Australia Health and Medical Research Institute | Australia |
| 2016 - ongoing | Chair | Women in Health Science Session | National Directions in Leukemia Research | Australia |
| 2016 - 2020 | Chair | ALL Stream of Australian Genomics Health Care Alliance (AGHA) | Australian Genomics Health Care Alliance (AGHA) | Australia |
| 2016 - 2020 | Member | Australian Genomics Health Care Alliance (AHGA) Executive | Australian Genomics Health Care Alliance (AHGA) | Australia |
| 2016 - 2016 | Member | New Directions in Leukemia Research Conference | NDLR | Australia |
| 2016 - ongoing | Chair | SAHMRI Genomics Executive Committee | - | - |
| 2015 - ongoing | Member | NHMRC Women in Health Science Faculty | - | - |
| 2015 - 2021 | Member | National Women in Health Science Faculty | NHMRC | Australia |
| 2015 - 2015 | Chair | Ross Wishart Memorial Award | Australian Society for Medical Research | Australia |
| 2015 - 2015 | Chair | CML and Myelproliferative Neoplasms | HAA | Australia |
| 2015 - 2015 | Member | US Ambassadors Round Table on Scientific Innovation | SAHMRI | Australia |
| 2014 - ongoing | Member | International Chronic Myeloid Leukemia Foundation (iCMLf) | - | Australia |
| 2014 - 2021 | Chair | Women in Science session | New Directions in Leukemia Research | Australia |
| 2014 - 2020 | Chair | Young Investigator session | New Directions in Leukemia Research | Australia |
| 2014 - 2016 | Member | SAHMRI post graduate student Committee | - | - |
| 2014 - 2015 | Advisory Board Member | (Malignant Haematology) HAA Organising Committee | - | Australia |
| 2014 - ongoing | Member | SA Translational Haematology Research Group Meetings | - | - |
| 2014 - 2014 | Chair | CML and Myeloproliferative Neoplasm Session | New Directions in Leukemia Research | Australia |
| 2014 - 2014 | Member | New Directions in Leukemia Research Conference | NDLR | Australia |
| 2013 - ongoing | Member | Research Executive Committee | SAHMRI | Australia |
| 2013 - 2015 | Founder | Haematology Statewide Translational Research Group | - | - |
| 2013 - 2013 | Member | BMS Advisory Board on Molecular Monitoring and Drug level Testing | BMS | Australia |
| 2012 - 2018 | Member | Bioscience Pillar Committee | South Australian Health and Medical Research Institute | Australia |
| 2012 - 2016 | Chair | Bioscience Pillar SA Comprehensive Cancer Consortium (SACCC) | SAHMRI | Australia |
| 2012 - 2015 | Member | NHMRC Research Translational faculty | NHMRC | Australia |
| 2012 - 2012 | Member | New Directions in Leukemia Research Conference | NDLR | Australia |
| 2012 - 2012 | Chair | Myeloid Leukaemia Session | New Directions in Leukemia Research | Australia |
| 2012 - 2012 | Chair | Leukaemia Foundation Early Career Scientists Session | New Directions in Leukemia Research | Australia |
| Date | Role | Membership | Country |
|---|---|---|---|
| 2016 - ongoing | Member | Franklin Women | - |
| 2015 - ongoing | Member | American Association for Cancer Research | - |
| 2014 - ongoing | Member | International CML Foundation | - |
| 2013 - ongoing | Member | International Children’s Oncology Group (COG) | - |
| 2010 - ongoing | Member | Australian Leukaemia and Lymphoma Group: Laboratory Scientific Committee (only non-clinician invited) | - |
| 2008 - ongoing | Member | Haematology Association of Australia and New Zealand | - |
| 2008 - ongoing | Member | Australian Leukaemia and Lymphoma Group (ALLG) | - |
| 2008 - ongoing | Member | European Haematology Association | - |
| 2008 - ongoing | Member | American Society of Haematology | - |
| Date | Institution | Department | Organisation Type | Country |
|---|---|---|---|---|
| 2016 - 2018 | Department of Premier and Cabinet | DPC and CARA | Legislative and political | Australia |
| 2015 - ongoing | Sigma Aldrich: Science Next Collaborative | - | - | - |
| 2013 - ongoing | BMS Advisory Board on Molecular Monitoring and Drug level Testing | - | - | - |
| 2008 - 2015 | Novartis Global Advisory Board Blood Level Testing and Mutational Analysis | - | Health services and related | Australia |
| Date | Role | Editorial Board Name | Institution | Country |
|---|---|---|---|---|
| 2016 - ongoing | Associate Editor | Journal of Blood Research & Hematologic Diseases | - | - |
